- Company
- Chong Kun Dang co-market Xofluza with Roche
- by Chon, Seung-Hyun Mar 23, 2020 06:27am
- Chong Kun Dang announced on the 19th that it recently signed a joint sales contract with Roche Korea for domestic distribution of the influenza treatment drug 'Xofluza'. Roche Korea and Chong Kun Dang jointly handle marketing and sales of Xofluza, and Chong Kun Dang is responsible for distribution. Xofluza is a drug used to treat influe
- Company
- Daewoong vs Allergan, patent dispute for two years
- by Kim, Jin-Gu Mar 20, 2020 06:25am
- The patent dispute between Daewoong Pharmaceutical and Allergan surrounding double-chin reduction treatment 'Belkyra' has not been concluded for the second year. According to the pharmaceutical industry on the 19th, the dispute began in March 2018, two years ago. Daewoong Pharmaceutical filed an invalidation trial of patents for Belkyra
- Company
- Salespersons got worked up about pharmacy’s poor sales
- by Jung, Hye-Jin Mar 19, 2020 06:26am
- Pharmaceutical industry sales managers are also suffering from the economic downturn in the medical institution caused by the aftermath of COVID-19. This is due to the fact that some retail pharmacies refuse to pay monthly payments to pharmaceutical salesmen due to a decrease in prescriptions. Even at the end of February, quite a few mana
- Company
- Samsung Biologics, CDO for alzheimer's treatment
- by Lee, Seok-Jun Mar 19, 2020 06:26am
- Samsung Biologics announced on the 17th that it has signed a CDO(Contract Development Organization) partnership with Aprinoia, a Taiwanese company that is developing Alzheimer's treatment. Aprinoia is a Taiwanese bio-venture with specialized technology in developing medical equipment and therapeutics for the diagnosis of degenerative neur
- Company
- Pharmaceutical industry focuses on Kyung-Hae Lee from GSK
- by Eo, Yun-Ho Mar 18, 2020 06:35am
- Personnel from executives of multinational pharmaceutical companies is on the list of proportional representative candidates for the United Future Party, attracting the attention of the industry. Kyung-Hae Lee(52) is the current vice president of BioGraphene and has been working in the Foreign Cooperation Department of GlaxoSmithKline (GSK
- Company
- FDA clears Celltrion’s 2nd HIV drug manufacturing plant
- by An, Kyung-Jin Mar 18, 2020 06:34am
- On Mar. 16, Celltrion announced its HIV treatment CT-G07-manufactuing Cheongju facility has passed the U.S. Food and Drug Administration’s (FDA) on-site inspection with no violation. Prior to CT-G07’s global launch, the on-site inspection was carried out to confirm the plant’s manufacturing facility and quality control system. In Janua
- Company
- 2nd anti-CGRP migraine drug Ajovy seeks approval in Korea
- by Eo, Yun-Ho Mar 17, 2020 06:28am
- A second anti-calcitonin gene-related peptide (CGRP) treatment for migraine is preparing for the Korean market. According to pharmaceutical industry sources, Handok Teva has submitted approval application on CGRP targeted migraine treatment Ajovy (fremanezumab) aiming for the Ministry of Food and Drug Safety’s nod by late June. Ajov
- Company
- Amid COVID-19 industry conflicted with working from home
- by Kim, Jin-Gu Mar 17, 2020 06:28am
- The pharmaceutical industry is in a dilemma of working from home. Pharmaceutical companies that have given an order to work from home to a part or all of the office are conflicted whether to continue or to stop working from home. Depending on companies, some of them have already been working remotely for over a month. But they complain it i
- Company
- Lamisil distribution halted over 2 months inventory issue
- by Jung, Hye-Jin Mar 17, 2020 06:28am
- The distribution status of GlaxoSmithKline (GSK) Consumer Health’s anti-fungal treatment Lamisil has been unstable for a while. After the co-promotion deal with Dongwha Pharmaceutical has ended last year, GSK’s Lamisil has not been properly supplied for over two months. Although Zuellig Pharma Korea is negotiating with GSK on the Korean
- Company
- Pharmaceuticals, growth rate to be cut in half
- by Eo, Yun-Ho Mar 17, 2020 06:28am
- It was analyzed that the domestic pharmaceutical industry would be suffered hard from the aftermath of COVID-19. Drug market research firm IQVIA predicted that the growth of the Korean pharmaceutical market this year will be only 4.4%, half of the previous year due to the spread of COVID-19. This analysis compared changes found in major
